TITLE

Immunotherapy

PUB. DATE
September 2005
SOURCE
CMAJ: Canadian Medical Association Journal;9/13/2005 Supplement, Vol. 173, pS46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the use of injection immunotherapy in treating allergic asthma. Immune modulation has been found to modify the underlying disease processes of asthma. Subcutaneous allergen, anti-Immunoglobulin E therapy, and intravenous immunoglobulin were among the immunotherapeutic strategies discussed. Implications of the research were also discussed.
ACCESSION #
24774481

 

Related Articles

  • Prospects for a Vaccine in Allergic Diseases and Asthma. Bousquet, J.; Yssel, H.; demoly, P. // BioDrugs;2000, Vol. 13 Issue 1, p61 

    Allergen-specific immunotherapy is widely used to treat allergic diseases, and current research is now focusing on the development of therapeutic vaccines acting on the IgE immune response following allergen challenge. The IgE immune response is dependent on genetic and environmental factors;...

  • New approaches to the treatment of asthma. Busse, William W. // Discover;Mar1999, Vol. 20 Issue 3, pS-25 

    Explores approaches to treating asthma. Limitations of anti-inflammatory therapy; Control of immunoglobulin E; Regulation of cellular inflammation; Locating the asthma gene.

  • Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Parks, Kevin W.; Casale, Thomas B. // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS33 

    Despite both efficacy and immunotolerogenic effects, many clinicians still are reluctant to use allergen-specific immunotherapy (SIT) because of the potential for acute allergic reactions. The anti-immunoglobulin E monoclonal antibody, omalizumab, is approved by the U.S. Food and Drug...

  • Evaluation of effectiveness of specific subcutaneous immunotherapy for patients with allergic rhinitis and asthma. Zandkarimi, M. R.; Hosseini, R. Farid; Jabbari, F.; Panah, H. Raf'at; Ghasemi, R.; Shirkani, A. // Iranian South Medical Journal;May2013, Vol. 16 Issue 2, p110 

    Background: Allergen immunotherapy involves the administration of gradually increasing quantities of specific allergens to patients with IgE-mediated conditions until a dose is reached that is effective in reducing disease severity from natural exposure. This study evaluated the clinical...

  • Type I IL-1 Receptor (IL-1RI) as Potential New Therapeutic Target for Bronchial Asthma. Jyh-Hong Lee; Li-Chieh Wang; Hsin-Hui Yu; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang // Mediators of Inflammation;2010, Vol. 2010, p1 

    The IL-1R/TLR family has been receiving considerable attention as potential regulators of inflammation through their ability to act as either activators or suppressors of inflammation. Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness, allergic inflammation,...

  • Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study. Cusack, R. P.; Sahadevan, A.; Lane, S. J. // QJM: An International Journal of Medicine;2016 Supplement, Vol. 109, p601 

    Introduction: Omalizumab is a recombinant humanized monoclonal antibody (anti-IgE) licensed for use in GINA 5 asthma or for chronic idiopathic urticaria. Many patients with asthma have concomitant allergic diseases such as dermatitis and sinusitis. IgE is also implicated in...

  • Is Immunotherapy for Asthma Worthwhile? Barnes, Peter J. // New England Journal of Medicine;2/22/96, Vol. 334 Issue 8, p531 

    Discusses the controversial role of allergen immunotherapy in the treatment of allergic asthma. Different studies on this issue; Benefits of the treatment that must be weighed against its adverse effects; Best possible test in the use of purified extract of ragweed; Unclear beneficial effects;...

  • EFFECTIVENESS OF OMALIZUMAB ON ASTHMA CONTROL AND LUNG FUNCTION IN SEVERE ALLERGIC ASTHMA PATIENTS IN THE CZECH REPUBLIC. Sedlák, V.; N. C. T. A. // Thorax;Dec2011 Supplement, pA111 

    Introduction Anti-IgE therapy (omalizumab) is indicated for severe persistent allergic asthma, which is uncontrolled despite appropriate therapy according to current GINA guidelines. Aim of this study Aim of this study was to describe changes of selected parameters (FEV1, life quality and...

  • Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Stei�, Jens-Oliver; Schmidt, Annesuse; N�hrlich, Lutz; Zimmer, Klaus-Peter; Rudloff, Silvia // Allergy & Asthma Proceedings;Jan/Feb2012, Vol. 33 Issue 1, p77 

    Omalizumab, a monoclonal anti-immunoglobulin E (IgE) antibody, is being successfully used as supplementary therapy to improve asthma control in children with severe persistent allergic asthma from the age of =6 years. Because the majority of commercially available IgE assays measure free as well...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics